No data to show
XCNQ
INNO
Market cap44mUSD
Jul 11, Last price
0.21CAD
1D
0.00%
1Q
23.53%
IPO
-16.00%
Name
Innocan Pharma Corp
Chart & Performance
P/E
—
P/S
1.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.34%
Rev. gr., 5y
%
Revenues
29m
+115.55%
Net income
-2m
L-60.98%
CFO
-2m
L-59.55%
Profile
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 29,437 115.55% | 13,657 433.69% | 2,559 1,205.61% | ||||
Cost of revenue | 30,684 | 17,460 | 8,825 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (1,247) | (3,803) | (6,266) | ||||
NOPBT Margin | |||||||
Operating Taxes | 1,181 | 214 | 1,000 | ||||
Tax Rate | |||||||
NOPAT | (2,428) | (4,017) | (6,267) | ||||
Net income | (1,834) -60.98% | (4,700) 20.85% | (3,889) -61.34% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 891 | ||||||
BB yield | -1.52% | ||||||
| Debt | |||||||
Debt current | 10 | 22 | 14 | ||||
Long-term debt | 10 | 44 | 54 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 1 | ||||||
Net debt | (4,988) | (3,819) | (4,879) | ||||
| Cash flow | |||||||
Cash from operating activities | (1,579) | (3,904) | (6,067) | ||||
CAPEX | (15) | (46) | (26) | ||||
Cash from investing activities | 54 | (84) | (31) | ||||
Cash from financing activities | 2,704 | 2,917 | 125 | ||||
FCF | (3,918) | (3,239) | (7,525) | ||||
| Balance | |||||||
Cash | 5,008 | 3,885 | 4,947 | ||||
Long term investments | |||||||
Excess cash | 3,536 | 3,202 | 4,819 | ||||
Stockholders' equity | (33,053) | (32,791) | (28,543) | ||||
Invested Capital | 40,085 | 37,210 | 34,802 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 280,041 | 257,004 | 248,953 | ||||
Price | 0.21 -32.26% | 0.31 44.19% | 0.22 -73.13% | ||||
Market cap | 58,809 -26.19% | 79,671 48.85% | 53,525 -70.20% | ||||
EV | 55,676 | 76,135 | 48,477 | ||||
EBITDA | (1,212) | (3,770) | (6,231) | ||||
EV/EBITDA | |||||||
Interest | 7 | 2 | |||||
Interest/NOPBT | |||||||